#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Advances and difficulties associated with the therapy of chronic HCV infection


Authors: P. Chalupa;  H. Rozsypal
Authors‘ workplace: Přednosta: doc. MUDr. Hanuš Rozsypal, CSc. ;  1. lékařská fakulta a Nemocnice Na Bulovce ;  Klinika infekčních a tropických nemocí ;  Univerzita Karlova v Praze
Published in: Prakt. Lék. 2018; 98(6): 246-252
Category: Reviews

Overview

The most important aspects associated with the therapy of chronic hepatitis C viral infection (HCV) using interferon-free therapy with DAA drugs (IFN-free DAA regimens) are mentioned. This therapy is very effective, safe, with minimum contraindications and adverse events. We must also permanently remember some crucial principles associated with this therapy: interaction with other medicaments, possibility of HBV reactivation and principles of care after successful treatment.

KEYWORDS:

HCV infection – HBV infection – interferon-free therapy – DAA drugs – HBV reactivation


Sources

1. Belperio PS, Shahoumian TA, Mole LA, et al. Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals. Hepatology 2017; 66(1): 27–36.

2. Cacoub P, Comarmond C, Domont F, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 2016; 3(1): 3–14.

3. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48(5): 835–847.

4. Dostálek M. Enzymatický systém cytochromu P450. Postgrad Med 2006; 8(1): 46–54.

5. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67(2): 370–398.

6. European Association for the Study of the Liver. EASL Recommendation on treatment of hepatitis C 2018. J Hepatol 2018, 69(2): 461–511.

7. Hůlek P, Urbánek P, a kol. Hepatologie. Praha: Grada Publishing 2018.

8. Chlíbek R, Smetana J, Šošovičková R, a kol. Výsledky séroprevalenční studie HCV infekce u dospělých v ČR. Hradecké virologické dny, Hradec Králové, 12.–13. 10. 2016 [online]. Dostupné z: https//www.fnhk.cz/fs1899/15chlibekprevalencehcvv-cr.pdf [cit. 2018-09-30].

9. Mastera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128(2): 343–350.

10. Sherman AC, Sherman KE. Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep 2015; 12(3): 353–361.

11. Suchopár J, Prokeš M. Přímo působící antivirotika proti hepatitidě typu C a jejich lékové interakce. Remedia 2018; 28(1): 95–108.

12. Urbánek P, Husa P, Šperl J, a kol. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C (HCV). Klin Mikrobiol Infekc Lek 2017; 23(1): 22–40.

Labels
General practitioner for children and adolescents General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#